Evidence map›Paper›PMID 38010229›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2024

High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience.

Hanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, Tina Cheng, Michael Chu, Nanette Cox-Kennett, D Scott Ernst, Amelie Fontaine, Sunita Ghosh, Daniel Y C Heng and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Hanbo ZhangDepartment of Medical Oncology and Hematology, University of Manitoba, Winnipeg, MB, Canada.
Nimira S AlimohamedDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Naveen S BasappaDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Tina ChengDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Michael ChuDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Nanette Cox-KennettDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
D Scott ErnstDepartment of Oncology, Western University, London, ON, Canada.
Amelie FontaineDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Sunita GhoshDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Daniel Y C HengDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Richard LittletonDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Scott NorthDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Cindy RailtonAlberta Health Services: CancerControl Alberta, Tom Baker Cancer Centre, Calgary, AB, Canada.
Irwindeep SandhuDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Trevor H StensonClinical Trials Unit, Cross Cancer Institute, Edmonton, AB Canada.
Douglas A StewartDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Christopher P VennerBC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC, Canada.
Peter VennerDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Michael P KolinskyDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
University of Alberta · CAUniversity of Calgary · CAAlberta Health Services · CAOntario Institute for Cancer Research · CAUniversity of British Columbia · CAUniversity of Manitoba · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHigh-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is standard therapy for metastatic germ cell tumors (mGCTs) in patients whose disease progresses during or after conventional chemotherapy. We conducted a retrospective review of HDC-ASCT in relapsed mGCT patients in the province of Alberta, Canada, over the past two decades.

methodsPatients with mGCTs who received HDC-ASCT at two provincial cancer referral centers from 2000-2018 were identified from institutional databases. Baseline clinical and treatment characteristics were collected, as well as overall survival (OS ) and disease-free survival (DFS). Relevant prognostic variables were analyzed.

resultsForty-three patients were identified. The median age was 28 years (range 19-56). A majority (95%) had non-seminoma histology and testis/retroperitoneal primary (84%). Twenty patients (47%) had poor-risk disease, as per The International Germ Cell Consensus Classification (IGCCC), at start of first-line chemotherapy. HDC-ASCT was used as second-line therapy in 65% of patients, and 58% of ASCT patients received tandem transplants. Median followup after ASCT was 22 months (range 2-181). At last followup, 42% of patients were alive without disease, including 3/7 (43%) of patients with primary mediastinal disease. Two-year and five-year DFS/OS ratios were 44%/65% and 38%/45%, respectively. Median OS and DFS for all patients were 30.0 months (13.3-46.6) and 8.0 months (0.9-15.1), respectively.

conclusionsWe found that HDC-ASCT is an effective salvage therapy in mGCT, consistent with existing literature. Patients appeared to benefit regardless of primary site. Although limited by small sample size, we found a numerical difference in DFS and OS between second- and third-line HDC-ASCT and single vs. tandem ASCT.

Identifiers

PMID38010229
PMCPMC10954282
OpenAlexW4388846524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.